More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$4.91B
EPS
-1.28
P/E ratio
--
Price to sales
8.31
Dividend yield
--
Beta
1.120437
Previous close
$49.70
Today's open
$49.38
Day's range
$48.25 - $51.18
52 week range
$22.59 - $68.73
show more
CEO
Eric Dube
Employees
497
Headquarters
San Diego, CA
Exchange
NASDAQ Global Market
Shares outstanding
95992155
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Travere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
Travere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
Seeking Alpha • Nov 16, 2026

Travere Therapeutics: FILSPARI Ongoing Growth Prospects Make Travere Compelling Buy
Travere Therapeutics has achieved two significant FDA approvals for FILSPARI, driving notable revenue growth. TVTX shares have nearly tripled since the initial 'Buy' rating in August 2025, reflecting strong momentum. With two FDA-approved revenue streams, TVTX now faces questions about sustaining its exceptional upward trajectory.
Seeking Alpha • Nov 16, 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on November 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 20 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 65,520 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted a.
Business Wire • Nov 12, 2026

Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened
Shares of Travere Therapeutics took a hit Tuesday after fewer than expected patients started treatment with its kidney drug, Filspari.
Investors Business Daily • Nov 3, 2026

Travere Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:Guggenheim Global Healthcare ConferencePresenting on Tuesday, November 10, 2026, at 8:00 a.m. ETStifel 2026 Healthcare ConferencePresenting on Wednesday, November 11, 2026, at 3:20 p.m. ETUBS Global Biopharma ConferencePresenting on Monday, November 16, 2026, at 11:20 a.m. GMTJefferies London Healthcare ConferencePresenting.
Business Wire • Nov 3, 2026

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
Travere Therapeutics NASDAQ: TVTX reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its kidney-disease and rare-disease pipeline.
MarketBeat • Nov 3, 2026

Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 3, 2026

Travere Therapeutics Reports Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its third quarter 2026 financial results and provided a corporate update. “Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “We remain early in reaching the more than 100,000 a.
Business Wire • Nov 2, 2026

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to earnings of $0.28 per share a year ago.
Zacks Investment Research • Nov 2, 2026

Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research • Nov 3, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Travere Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.